Jon Heinrichs

Jon Heinrichs leads IAVI’s discovery science efforts. In this role, he oversees activities at IAVI’s research laboratories in Brooklyn, NY; La Jolla, CA; and Faridibad, India, working with the teams to set strategic and operational direction and ensuring seamless collaboration across the facilities. He is also responsible for driving the discovery research strategy for IAVI in collaboration with the executive team and the disease area leads.

Heinrichs has had a distinguished career in vaccine R&D, with thirty years of experience at leading biopharmaceutical companies, including Sanofi Pasteur, Merck, and MedImmune (now part of AstraZeneca). Most recently he served as global head of innovation and emerging sciences at Sanofi and led development of the monoclonal antibody nirsevimab (Beyfortus), now licensed for the prevention of RSV disease in infants.

Heinrichs earned his Ph.D. and M.S. in microbiology and molecular genetics from Rutgers University and completed a post-doctoral fellowship in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University in New York.